Skip to main content

Exploiting GLIOblastoma intractability to address European research TRAINing needs in translational brain tumour research, cancer systems medicine and integrative multi-omics

Objective

Glioblastoma (GBM) is the most frequent, aggressive and lethal of all brain tumours. It has a universally fatal prognosis with 85% of patients dying within two years. New treatment options and effective precision medicine therapies are urgently required. This can only be achieved by focused multi-sectoral industry-academia collaborations in newly emerging, innovative research disciplines. GLIOTRAIN will exploit the intractability of GBM to address European applied biomedical research training needs. The ETN, which comprises 9 beneficiaries and 14 partner organisations from 8 countries, will train 15 innovative, creative and entrepreneurial ESRs. The research objective of GLIOTRAIN is to identify novel therapeutic strategies for application in GBM, while implementing state of the art next generation sequencing, systems medicine and integrative multi-omics to unravel disease resistance mechanisms. Research activities incorporate applied systems medicine, integrative multi-omics leveraging state of the art platform technologies, and translational cancer biology implementing the latest clinically relevant models. The consortium brings together leading European and international academics, clinicians, private sector and not-for-profit partners across GBM fields of tumour biology, multi-omics, drug development, clinical research, bioinformatics, computational modelling and systems biology. Thus, GLIOTRAIN will address currently unmet translational research and clinical needs in the GBM field by interrogating innovative therapeutic strategies and improving the mechanistic understanding of disease resistance. The GLIOTRAIN ETN addresses current needs in academia and the private sector for researchers that have been trained in an environment that spans translational research, medicine and computational biology, and that can navigate confidently between clinical, academic and private sector environments to progress applied research findings towards improved patient outcomes.

Call for proposal

H2020-MSCA-ITN-2017
See other projects for this call

Coordinator

ROYAL COLLEGE OF SURGEONS IN IRELAND
Address
Saint Stephen's Green 123
2 Dublin
Ireland
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 1 062 698,40

Participants (8)

UNIVERSITY OF STUTTGART
Germany
EU contribution
€ 498 432,96
Address
Keplerstrasse 7
70174 Stuttgart
Activity type
Higher or Secondary Education Establishments
LUXEMBOURG INSTITUTE OF HEALTH
Luxembourg
EU contribution
€ 250 560
Address
Val Fleuri 84
1526 Luxembourg
Activity type
Research Organisations
VIB VZW
Belgium
EU contribution
€ 667 672,80
Address
Rijvisschestraat 120
9052 Zwijnaarde - Gent
Activity type
Research Organisations
INSTITUT DU CERVEAU ET DE LA MOELLE EPINIERE
France
EU contribution
€ 262 875,60
Address
Boulevard De L'hopital 47
75013 Paris
Activity type
Research Organisations
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Netherlands
EU contribution
€ 510 748,56
Address
Dr Molewaterplein 40
3015 GD Rotterdam
Activity type
Higher or Secondary Education Establishments
GENEXPLAIN GMBH
Germany
EU contribution
€ 249 216,48
Address
Am Exer 19 B
38302 Wolfenbuttel
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
INFORMATION TECHNOLOGY FOR TRANSLATIONAL MEDICINE (ITTM) SA
Luxembourg
EU contribution
€ 250 560
Address
27 Rue Henri Koch
4354 Esch Sur Alzette
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
AGILENT TECHNOLOGIES BELGIUM NV

Participation ended

Belgium
EU contribution
€ 84 007,20
Address
De Kleetlaan 5
1831 Diegem
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)

Partners (14)

CANCER TRIALS IRELAND CLG
Ireland
Address
Innovation House Dcu Alpha Finglas Road Old
D11 KXN4 Dublin 11
Activity type
Other
Champions Oncology, Inc.
United States
Address
One University Plaza
Hackensack, Nj
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
INSILICO BIOTECHNOLOGY AG
Germany
Address
Meitnerstrasse 9
70563 Stuttgart
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
YUMAB GmbH
Germany
Address
Rebenring 33
38106 Braunschweig
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
CARTHERA
France
Address
47 Boulevard De L'hopital
75013 Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
BMS France
France
Address

Argonay
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
TEVA PHARMACEUTICALS EUROPE B.V.
Netherlands
Address
Piet Heinkade 107
1019 GM Amsterdam
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Oncurious NV
Belgium
Address
Gaston Geenslaan 1
3001 Leuven
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Pepscope BV
Netherlands
Address
Dantelaan 83
3533 VB Utrecht
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
MIMETAS BV
Netherlands
Address
Jh Oortweg 19
2333CH Leiden
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
International Brain Tumour Alliance
United Kingdom
Address
C/o Hamlins Llp, Roxburghe House, Regent Street 273 - 287
W1B 2AD London
Activity type
Other
MEDIZINISCHE HOCHSCHULE HANNOVER
Germany
Address
Carl-neuberg-strasse 1
30625 Hannover
Activity type
Higher or Secondary Education Establishments
UNIVERSITE DU LUXEMBOURG
Luxembourg
Address
2 Avenue De L'universite
4365 Esch-sur-alzette
Activity type
Higher or Secondary Education Establishments
KATHOLIEKE UNIVERSITEIT LEUVEN
Belgium
Address
Oude Markt 13
3000 Leuven
Activity type
Higher or Secondary Education Establishments